HepaHope, Inc.
HepaHope, Inc. carries out increase in cash capital
HepaHope, Inc. / Capital Increase Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. HepaHope, Inc. carries out increase in cash capital - Distribution partner HepaHope Korea expands its stake Irvine (California, USA), July 7, 2009 - The biopharma company HepaHope, Inc. (symbol: 0HH1) has issued 484,000 new shares at EUR 1.00 each, i.e. at the current share price, as part of a capital increase. This provides the company with EUR 484,000 in additional funds which are earmarked for financing the upcoming clinical trials of its most important product - HepaPheresis(TM) System, a treatment for patients with acute and chronic liver complaints. The additional shares, which the company originally planned to place in the IPO, were completely subscribed by the distribution partner HepaHope Korea (symbol: 039350.KQ), which is listed in South Korea. The company therefore expands its strategic stake in HepaHope, Inc. to 10 %. The capital increase is effective as of today. This capital measure raises the number of outstanding shares in HepaHope, Inc. to 71,316,131. Disclaimer No stock exchange or regulatory authority has approved or disapproved of the information contained herein. The securities offered were not registered under the United States Securities Act of 1933 (the '1933 Act') or the securities laws of any state and may not be offered or sold in the United States or to U.S. persons, except pursuant to registration under the 1933 Act or pursuant to an available exemption from such registration requirements. In particular, the securities are subject to a 'distribution compliance period' of at least one year during which they may not be offered or sold to persons in the United States or U.S. persons except in transactions exempt from registration under the 1933 Act. About HepaHope: HepaHope, Inc. is a biopharmaceutical company focused on research, development and commercialization of biologic products designed to address the needs of patients with liver failure. The Company's leading proprietary technology, the HepaPheresis(TM) System, is based on an Organ Slice Cultivation Technology which aims to maintain the functionality of various organs out of the body (ex vivo) in order to better support liver failure patients. The HepaPheresis(TM) System is currently being prepared for Phase I clinical trials. HepaHope's patented core technology for organ slice cultivation is also the foundation of other product candidates in the pipeline of this company in the oncology testing market and the drug development market. The members of the management and science advisory board of the company represent leading scientists in liver research. HepaHope was founded in February 1999. The offices and research facilities of the US Company are both located in California. For further information visit: www.hepahope.com For media inquiries: HepaHope, Inc Bhavesh Singh Chief Financial Officer P + 1 949 421 3617 M + 1 201 920 1819 Investor Relations IR.on AG Achim Josten Dariusch Manssuri T +49 221. 9140.970 F +49 221. 9140.978 E-mail: info@ir-on.com 07.07.2009 Financial News transmitted by DGAP ---------------------------------------------------------------------- Language: English Issuer: HepaHope, Inc. 30 Fairbanks, Suite 110 CA 92618 Irvin Vereinigte Staaten von Amerika Phone: 001 9494213600 Fax: 001 9494213680 E-mail: investor@hepahope.com Internet: http://www.hepahope.com ISIN: US42689N1090, USU425541021 WKN: A0RMY4, A0RLC1 Listed: Freiverkehr in Düsseldorf, Stuttgart; Open Market (Entry Standard) in Frankfurt End of News DGAP News-Service ---------------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found